Cancer chemoprevention in the 21st century: Genetics, risk modeling, and molecular targets

Journal of Clinical Oncology

Volumn 18, Issue 21 SUPPL., 2000, Pages

  Waun Ki Hong, ^a   Spitz, M R ^a   Lippman, S M ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA TOCOPHEROL; BCG VACCINE; BETA CAROTENE; BUDESONIDE; CANCER VACCINE; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; EFLORNITHINE; ENZYME INHIBITOR; EPIGALLOCATECHIN GALLATE; ESTROGEN RECEPTOR AFFECTING AGENT; FENRETINIDE; HISTONE DEACETYLASE INHIBITOR; HORMONE RECEPTOR AFFECTING AGENT; ISOTHIOCYANIC ACID; ISOTRETINOIN; LIPOXYGENASE INHIBITOR; MATRIX METALLOPROTEINASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN KINASE C INHIBITOR; RALOXIFENE; RETINOID; SELENIUM; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMOXIFEN; TRITERPENOID; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN D DERIVATIVE;

ADENOMATOUS POLYP; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER PREVENTION; CANCER RISK; CLINICAL TRIAL; CONFERENCE PAPER; DIGESTIVE SYSTEM CANCER; HEAD CANCER; HUMAN; LUNG CANCER; NECK CANCER; PRIORITY JOURNAL; RISK ASSESSMENT; SKIN CANCER; UROGENITAL TRACT CANCER;

AWARDS AND PRIZES; CHEMOPREVENTION; HUMANS; NEOPLASMS;

EID: 0034332541     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (82)

1. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids)
2. Tamoxifen for prevention of breast cancer: Report of the national surgical adjuvant breast and bowel project P-1 study
3. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis
4. Cancer chemoprevention
5. Cancer chemoprevention: Progress and promise
6. Tamoxifen prevention of breast cancer: An instance of the fingerpost
7. Recent advances in head and neck cancer: Larynx preservation and cancer chemoprevention - The Seventeenth Annual Richard and Hinda Rosenthal Foundation Award Lecture
8. 13-cis-retinoic acid in the treatment of oral leukoplakia
9. Comparison of low-dose isotretinoin with beta-carotene to prevent oral carcinogenesis
10. Low-dose isotretinoin versus β-carotene to prevent oral carcinogenesis: Long-term follow-up
11. Mediation of N-(4-hydroxyphenyl)retinamide-induced apoptosis in human cancer cells by different mechanisms
12. Retinamide activity in retinoid-resistant oral premalignant lesions (OPLs): Translational correlative studies
13. Suppression of retinoic acid receptor beta in oral premalignant lesions and its upregulation by isotretinoin
14. Frequent microsatellite alterations at chromosome 9p21 and 3p14 in oral premalignant lesions and its value in cancer risk assessment
15. Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia
16. A case-control study confirms that microsatellite assay can identify patients at risk of developing oral squamous cell carcinoma within a field of cancerization
17. Frequent inactivation of p16 in oral premalignant lesions
18. Telomerase activity in the pathogenesis of head and neck squamous cell carcinoma
19. Biomarkers as intermediate endpoints in chemoprevention trials
20. Predicting cancer development in oral leukoplakia: Ten years of translational research
21. p53 and retinoid chemoprevention of oral carcinogenesis
22. Biochemoprevention for dysplastic lesions of the upper aerodigestive tract
23. Alteration of p53 gene and protein expression and biochemopreventive therapy in patients with advanced premalignant lesions of the head and neck
24. Pheno-type and genotype in advanced premalignant head and neck lesions after chemopreventive therapy
25. Second malignant tumors in head and neck squamous cell carcinoma: The overshadowing threat for patients with early-stage disease
26. Head and neck cancer
27. Prevention of second primary tumors with isotretinoin in squamous cell carcinoma of the head and neck
28. Prevention of second primary tumors with isotretinoin in squamous cell carcinoma of the head and neck: Long-term follow-up
29. Phase II study of biologic adjuvant therapy to prevent recurrence and second primary tumors (SPT) in stage III/IV head and neck cancer
30. Benzo[a]pyrene diol epoxide and bleomycin sensitivity of lymphocytes and head and neck cancer susceptibility
31. Chromosome sensitivity to bleomycin-induced mutagenesis, an independent risk factor for upper aerodigestive tract cancers
32. Mutagen sensitivity as a risk factor for second malignant tumors following malignancies of the upper aerodigestive tract
33. Correlates of mutagen sensitivity in patients with upper aerodigestive tract cancers
34. Randomized placebo-controlled trial of isotretinoin in chemoprevention of bronchial squamous metaplasia
35. N(4-hydroxyphenyl)retinamide in the chemoprevention of squamous metaplasia and dysplasia of the bronchial epithelium
36. Lung carcinoma in former smokers
37. Clonal genetic alterations in the lungs of current and former smokers
38. Nuclear retinoid receptor beta in bronchial epithelium of smokers before and during chemoprevention
39. Retinoic acid receptor-beta as a prognostic indicator in stage I non-small cell lung cancer
40. Not yet standard: Retinoids versus second primary tumors
41. Higher lung cancer risk for younger African-Americans with the pro/pro p53 genotype
42. The role of DNA repair capacity in susceptibility to lung cancer: A review
43. Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans
44. Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: A case-control study
45. Mutagen sensitivity exhibits a dose-response relationship in case-control studies
46. Dietary intake of isothiocyanates: Evidence of a joint effect with glutathione transferase polymorphisms in lung cancer risk in current smokers
47. Plasma levels of insulin-like growth factor-I and lung cancer risk: A case-control analysis
48. Joint effect of insulin-like growth factors and mutagen sensitivity in lung cancer risk
49. Case-control study of the D2 dopamine receptor gene and smoking status in lung cancer patients
50. A lung cancer case-control study of the D2 dopamine receptor gene polymorphisms, smoking, and family history of smoking-related cancers among African- and Mexican-Americans
51. Chemoprevention of colorectal cancer
52. Aspirin and the risk of colorectal cancer in women
53. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis
54. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis
55. Apoptosis in cancer
56. Aspirin, NSAIDs, and colon cancer prevention: Mechanisms?
57. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction
58. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: Independence from COX-2 protein expression
59. 15-LOX-1: A novel molecular target of non-steroidal anti-inflammatory drug-induced apoptosis in colorectal cancer cells
60. Loss of retinoic acid receptor-beta expression is an early event during esophageal carcino-genesis
61. Expression and up-regulation of retinoic acid receptor-β is associated with retinoid sensitivity and colony formation in esophageal cancer cell lines
62. Lack of correlation between expression of retinoic acid receptor-beta and loss of heterozygosity on chromosome band 3p24 in esophageal cancer
63. Aspirin induction of apoptosis in esophageal cancer: A potential for chemoprevention
64. SELECT: The Selenium and Vitamin E Cancer Prevention Trial rationale and design
65. Selenium effects on prostate cell growth
66. Retinoids in the chemoprevention of bladder cancer
67. 13-cis retinoic acid plus interferon-α2a: Effective therapy for advanced squamous cell carcinoma of the skin
68. Expression of interferon-beta is associated with growth arrest of murine and human epidermal cells
69. Expression of a retinoid inducible tumor suppressor, tazarotene inducible gene-3, is decreased in psoriasis and skin cancer
70. Expression of protein mediators of type I interferon signaling in human squamous cell carcinoma of the skin
71. Cloning and characterization of the human retinoid X receptor alpha gene: Conservation of structure with the mouse homolog
72. Progressive decrease in nuclear retinoic acid receptor β messenger RNA level during breast carcinogenesis
73. Image morphometric nuclear grading of intraepithelial neoplastic lesions with applications to cancer chemoprevention trials
74. Novel translational model for breast cancer chemoprevention study: Accrual to a presurgical intervention with tamoxifen and 4-HPR
75. Molecular epidemiology and retinoid chemoprevention of head and neck cancer
76. Retinoid chemoprevention of aerodigestive cancer: From basic research to the clinic
77. Recent advances in chemoprevention of cancer
78. Prevention in the next millennium: Report of the Chemoprevention Working Group to the American Association for Cancer Research
79. Retinoid receptor-dependent and -independent effects of N-(4-hydroxyphenyl)retinamide in F9 embryonal carcinoma cells
80. Primary cancer prevention trials
81. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma